As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

  5/7/24  Y-mAbs Therapeutics, Inc.         10-Q        3/31/24   86:8.2M                                   Toppan Merrill Bridge/FA 
  5/7/24  Y-mAbs Therapeutics, Inc.         8-K:2,9      5/7/24   11:375K                                   Toppan Merrill Bridge/FA 
 4/29/24  Y-mAbs Therapeutics, Inc.         8-K:5       4/25/24    1:20K                                    Toppan Merrill/FA        
 4/29/24  Y-mAbs Therapeutics, Inc.         ARS        12/31/23    1:2.1M                                   Toppan Merrill Bridge/FA 
 4/29/24  Y-mAbs Therapeutics, Inc.         DEFA14A                1:276K                                   Toppan Merrill Bridge/FA 
 4/29/24  Y-mAbs Therapeutics, Inc.         DEF 14A     6/11/24    1:1.6M                                   Toppan Merrill Bridge/FA 
  4/8/24  Paradigm Biocapital Advisors LP   SC 13G                 2:65K  Y-mAbs Therapeutics, Inc.         Toppan Merrill/FA        
          Paradigm Biocapital Advisors GP LLC³
          Paradigm BioCapital International Fund Ltd.³
          Senai Asefaw, M.D.³
 3/14/24  Tagliaferri Mary                  4          Director²   1:7K   Y-mAbs Therapeutics, Inc.         Toppan Merrill/FA        
 3/14/24  Y-mAbs Therapeutics, Inc.         8-K:5,7,9    3/8/24   11:203K                                   Toppan Merrill/FA        
  3/8/24  Tagliaferri Mary                  3          Director²   2:10K  Y-mAbs Therapeutics, Inc.         Toppan Merrill/FA        
  3/7/24  Rajah Vignesh                     4          Officer²    1:6K   Y-mAbs Therapeutics, Inc.         Toppan Merrill/FA        
  3/7/24  Gad Thomas                        4          Dir.,Off.²  1:6K   Y-mAbs Therapeutics, Inc.         Toppan Merrill/FA        
  3/7/24  Smith Susan Laura                 4          Officer²    1:4K   Y-mAbs Therapeutics, Inc.         Toppan Merrill/FA        
  3/6/24  Smith Susan Laura                 144                    1:4K   Y-mAbs Therapeutics, Inc.         Merrill Lync… Inc/PES/FA 
  3/6/24  Rajah Vignesh                     144                    1:4K   Y-mAbs Therapeutics, Inc.         Merrill Lync… Inc/PES/FA 
  3/5/24  Gad Thomas                        144          3/5/24    1:4K   Y-mAbs Therapeutics, Inc.         Merrill Lync… Inc/PES/FA 
  3/4/24  Y-mAbs Therapeutics, Inc.         8-K:5,7,9   2/29/24   11:236K                                   Toppan Merrill/FA        
 2/29/24  Y-mAbs Therapeutics, Inc.         S-8         2/29/24    4:185K                                   Toppan Merrill Bridge/FA 
 2/29/24  Y-mAbs Therapeutics, Inc.         10-K       12/31/23  101:10M                                    Toppan Merrill Bridge/FA 
 2/29/24  Y-mAbs Therapeutics, Inc.         8-K:2,9     2/29/24   11:302K                                   Toppan Merrill/FA        

____________
¹	Filing/Form Types:
	3	Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 { The Filer is an Insider² of the Issuer }.
	4	Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 { The Filer is an Insider² of the Issuer }.
	8-K	Current Report — Form 8-K { Item 1: Business & Operations;  2: Financial Info;  3: Securities & Trading;  4: Accountants & Accounting;  5: Governance & Management;  6: Asset-Backed Securities;  7: Disclosures;  8: Events;  9: Financials }.
	10-K	Annual Report — Form 10-K.
	10-Q	Quarterly Report — Form 10-Q.
	144	Notice of a Proposed Sale of Securities by an Insider — Form 144 { The Filer is an Insider² of the Issuer }.
	ARS	Annual Report to Security Holders.
	DEF 14A	Definitive Proxy Statement — Schedule 14A.
	DEFA14A	Definitive Additional Proxy Soliciting Material — Schedule 14A.
	S-8	Registration Statement – Securities for an Employee Benefit Plan — Form S-8.
	SC 13G	Statement of Acquisition of Beneficial Ownership by a “Passive” Investor — Schedule 13G.
²	Insider:  The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer.
³	Group Member:  A Registrant or non-Registrant party to this Filing made by a Group.